ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update...
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup....
ICON plc , (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies...
Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cabaletta Bio (CABA – Research Report) and Icon (ICLR – Research Report) with bullish sentiments.Elevate...
Robert W. Baird analyst Eric Coldwell maintained a Buy rating on Icon today and set a price target of $226.00. The company’s shares opened today at $183.56.Elevate Your Investing Strategy: Take advantage...
Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Icon today and set a price target of $240.00. The company’s shares closed yesterday at $186.65.Elevate Your Investing Strategy:...
ICON plc , (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday,...
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the...